These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37776485)

  • 21. Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects.
    Reyes M; Hoch M; Brossard P; Dingemanse J
    Pharmacology; 2014; 94(5-6):223-9. PubMed ID: 25402365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitigation of Initial Cardiodynamic Effects of the S1P
    Juif PE; Hoch M; Vaclavkova A; Krause A; Bush J; Dingemanse J
    J Clin Pharmacol; 2017 Mar; 57(3):401-410. PubMed ID: 27558098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects.
    Scherz MW; Brossard P; D'Ambrosio D; Ipek M; Dingemanse J
    J Clin Pharmacol; 2015 Jun; 55(6):688-97. PubMed ID: 25612299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator.
    Krause A; Brossard P; D'Ambrosio D; Dingemanse J
    J Pharmacokinet Pharmacodyn; 2014 Jun; 41(3):261-78. PubMed ID: 24930034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absolute Bioavailability of Ponesimod, a Selective S1P
    Boehler M; Juif PE; Hoch M; Dingemanse J
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):129-134. PubMed ID: 26883438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects.
    Juif PE; Hoch M; D'Ambrosio D; Dingemanse J
    Drugs R D; 2015 Jun; 15(2):203-10. PubMed ID: 25939333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ponesimod for the treatment of relapsing multiple sclerosis.
    Baldin E; Lugaresi A
    Expert Opin Pharmacother; 2020 Nov; 21(16):1955-1964. PubMed ID: 32808832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.
    Gisleskog PO; Valenzuela B; Scherz T; Burcklen M; Pérez-Ruixo JJ; Poggesi I
    Clin Pharmacokinet; 2021 Sep; 60(9):1227-1237. PubMed ID: 33914286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis.
    Valenzuela B; Poggesi I; Luyckx N; Vaclavkova A; Pérez-Ruixo JJ
    Clin Pharmacol Ther; 2023 Mar; 113(3):692-703. PubMed ID: 36524329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.
    Piali L; Froidevaux S; Hess P; Nayler O; Bolli MH; Schlosser E; Kohl C; Steiner B; Clozel M
    J Pharmacol Exp Ther; 2011 May; 337(2):547-56. PubMed ID: 21345969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.
    Hoch M; Darpo B; Brossard P; Zhou M; Stoltz R; Dingemanse J
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):429-37. PubMed ID: 25287214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling the Effect of the Selective S1P
    Lott D; Krause A; Seemayer CA; Strasser DS; Dingemanse J; Lehr T
    Pharm Res; 2017 Mar; 34(3):599-609. PubMed ID: 28028771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison.
    Swallow E; Pham T; Patterson-Lomba O; Yin L; Gomez-Lievano A; Liu J; Tencer T; Gupte-Singh K
    Mult Scler Relat Disord; 2023 Mar; 71():104551. PubMed ID: 36791623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiodynamic Interactions between Two S1P
    Juif PE; Ufer M; Dingemanse J
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31266149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of multiple-dose ponesimod, a selective S1P
    Jurcevic S; Juif PE; Hamid C; Greenlaw R; D'Ambrosio D; Dingemanse J
    Drug Des Devel Ther; 2017; 11():123-131. PubMed ID: 28096659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans.
    Reyes M; Hoch M; Brossard P; Wagner-Redeker W; Miraval T; Dingemanse J
    Xenobiotica; 2015 Feb; 45(2):139-49. PubMed ID: 25188442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations.
    D'Ambrosio D; Steinmann J; Brossard P; Dingemanse J
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):103-9. PubMed ID: 25519470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P
    Kihara Y; Jonnalagadda D; Zhu Y; Ray M; Ngo T; Palmer C; Rivera R; Chun J
    FASEB J; 2022 Feb; 36(2):e22132. PubMed ID: 34986275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis.
    Valenzuela B; Pérez-Ruixo JJ; Leirens Q; Ouwerkerk-Mahadevan S; Poggesi I
    Clin Pharmacokinet; 2021 Sep; 60(9):1239-1250. PubMed ID: 33914285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes.
    You S; Piali L; Kuhn C; Steiner B; Sauvaget V; Valette F; Clozel M; Bach JF; Chatenoud L
    PLoS One; 2013; 8(10):e77296. PubMed ID: 24204793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.